What are the latest results of the BMS‑986460 (NCT06067841) trial in men with metastatic castration‑resistant prostate cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No Published Results Available for BMS-986460 (NCT06067841)

There are currently no published results for the BMS-986460 trial (NCT06067841) in men with metastatic castration-resistant prostate cancer. The evidence provided contains information about a different BMS compound (BMS-986365/CC-94676), which is an androgen receptor ligand-directed degrader, but this is not the same agent as BMS-986460.

What We Know About BMS-986365 (Different Trial)

The available research evidence describes BMS-986365 (CC-94676), tested in the CC-94676-PCA-001 trial (NCT04428788), not BMS-986460 1. This is a distinct compound with different mechanisms and trial identifiers.

BMS-986365 Trial Results (For Context Only)

For BMS-986365 in heavily pretreated mCRPC patients 1:

  • PSA50 response: 32% overall at highest doses (400-900 mg twice daily); 50% at 900 mg dose
  • Median rPFS: 6.3 months overall; 8.3 months at 900 mg dose
  • Safety profile: Most common adverse events were asymptomatic QT prolongation (47%) and bradycardia (34%)
  • Efficacy by prior treatment: Longer rPFS in chemotherapy-naive patients (16.5 months) versus those with prior chemotherapy (5.5 months)
  • Mechanism: Dual AR degrader and antagonist, showing activity regardless of AR ligand-binding domain mutation status

Important Caveats

  • The drug labels provided 2 are for maropitant citrate (an antiemetic for dogs), which is completely unrelated to prostate cancer treatment and appears to be an error in the evidence compilation
  • NCT06067841 may be an ongoing trial without published results, or the trial identifier may need verification
  • For current treatment decisions in mCRPC, refer to established guidelines 3 recommending ARPIs, PARPi (for BRCA1/2 alterations), chemotherapy, or radiopharmaceuticals based on prior treatment history

To obtain actual results for NCT06067841, check ClinicalTrials.gov directly or contact the trial sponsor for any available data.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.